Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis

Ceftolozane/tazobactam is approved for the treatment of patients from birth to <18 y old with complicated urinary tract infections (cUTI). This post hoc analysis evaluated the safety, efficacy, and pharmacokinetics (PK) of ceftolozane/tazobactam compared with meropenem in neonates and young infan...

Descripción completa

Detalles Bibliográficos
Autores principales: Roilides, Emmanuel, Bradley, John S., Lonchar, Julia, Huntington, Jennifer A., Wickremasingha, Prachi, Su, Feng-Hsiu, Bruno, Christopher J., Johnson, Matthew G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581202/
https://www.ncbi.nlm.nih.gov/pubmed/37698430
http://dx.doi.org/10.1128/spectrum.01800-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581202/
https://www.ncbi.nlm.nih.gov/pubmed/37698430
http://dx.doi.org/10.1128/spectrum.01800-23

Ejemplares similares